NLS Pharma News

Sponsored content

ViewLinc Cloud Suite supports life science innovation from laboratory to regulated operations

Vaisala introduces ViewLinc Cloud Suite, a cloud-based environmental monitoring solution that helps organizations start professional-quality monitoring immediately and scale as needs evolve, complemented by Vaisala Care for ViewLinc lifecycle services in selected markets.

Pharma Business – November 19, 2026

FDA grants Medivir rare pediatric disease designation

The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Medivir’s MIV-711 for the treatment of osteogenesis imperfecta (OI), a rare disorder that causes fragile bones. If the drug is eventually approved, the designation could earn Medivir a Priority Review Voucher – an asset that has sold for between USD 180 million and USD 210 million in 2026.

Sponsored content

Build a Targeted Biomarker Strategy for Your Program

Turn biological signals into meaningful development insights with a biomarker strategy tailored to your program. 

Acquisition – November 17, 2026

Attana to merge with BioNavis

Swedish Attana has agreed to acquire all shares in Finnish BioNavis, combining its QCM biosensor technology with BioNavis’ MP-SPR instruments to create a broader offering in analytical instruments for life science and materials science.

Pharma Business – November 17, 2026

EU approves Sobi’s Tryngolza for severe hypertriglyceridemia

The European Commission has approved Sobi’s Tryngolza (olezarsen) for adults with severe hypertriglyceridemia (sHTG) and triglyceride levels of at least 880 mg/dL, making it the first RNA-targeted therapy authorized in the EU for this patient group.

Clinical Trials

Profiles in Pharma

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.